Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Cellares is cutting 100 jobs after Bristol Myers ends $380m CAR-T deal
Cellares will permanently eliminate 100 South San Francisco positions after Bristol Myers Squibb terminated a manufacturing partnership worth up to $380 million, saying the Cell Shuttle platform could not meet commercial Breyanzi requirements, an assessment Cellares disputes.
Aptar names Gael Touya CEO as quarterly sales cross $1bn for first time
Gael Touya has become AptarGroup CEO after more than 30 years across its Pharma, Beauty and Closures operations, inheriting a company whose quarterly sales crossed $1 billion for the first time but whose adjusted EBITDA margin fell to 20.7% amid pharmaceutical destocking and investment.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.
CRISPR Therapeutics advances one-time cardiovascular strategy as CTX310 lipid reductions persist for a year
CTX310 sustains deep lipid reductions for one year as CRISPR Therapeutics expands its cardiovascular gene-editing strategy. See what comes next.
Biohaven gets $400m near-term cash as SK Biopharmaceuticals takes opakalim rights
SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash and up to $395 million in additional milestones for global rights to opakalim and its Kv7 platform, while pivotal epilepsy data remain pending.
Corvus Pharmaceuticals builds momentum around soquelitinib as pivotal lymphoma study continues
Corvus Pharmaceuticals strengthens its soquelitinib story with durable T-cell lymphoma data in Blood. Read what it means for Phase 3 and CRVS stock.
Roivant’s LISRAYA wins FDA approval as $26bn biotech enters commercial autoimmune era
Roivant has secured FDA approval for LISRAYA in adults with dermatomyositis, converting brepocitinib into a commercial product while retaining multiple late-stage opportunities in other autoimmune diseases.
Aspen Pharmacare (JSE: APN) ends FY26 with net cash after R28bn APAC sale
Aspen expects continuing-operations normalised earnings per share to rise 19%-24% after a sharp second-half recovery, while the APAC disposal transformed its balance sheet.
Teva gets Priority Review for ecopipam just months after buying Emalex for $700m
Teva has secured FDA Priority Review for ecopipam in pediatric Tourette syndrome, putting a late first-quarter 2027 decision date on the key asset acquired through its $700 million purchase of Emalex Biosciences.
A small pancreatic cancer study just sent RenovoRx shares soaring. The biggest test is still ahead
RenovoRx shares surge after TAMP data show 51% targeted gemcitabine extraction. See why TIGeR-PaC survival results remain the key catalyst.